This highlights the potential use of semaglutide due to its low cost and superior performance
August 2, 2024: Comprehensive Data Analysis Suggests Rybelsus May Be Associated with an Increased Risk of Blood Clots, DVT, and Pulmonary Embolisms Trial data from an efficacy study point to an increased risk of blood clots for people taking semaglutide drugs, like Rybelsus, for type 2 diabetes
When prescribed for weight loss, this constitutes off-label usea practice permitted under medical judgment but outside the FDA-approved indication
The Paragraph IV clock for Rezdiffra starts on March 14, 2028 (four years after approval, the NCE-1 date under Hatch-Waxman)
GLP-1 weight loss programs work best when combined with nutritional support, activity guidance, and ongoing medical oversight